BACKGROUND: The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in patients with clear-cell histology (ccRCC). We assessed outcome with these mammalian target of rapamicin (mTOR) inhibitors in two subsets of kidney cancer: sarcomatoid variant ccRCC and nonclear-cell RCC. PATIENTS AND METHODS: Baseline clinical features, information on prior treatment, and histologic subtypes were collected for patients previously treated with rapalogs for metastatic RCC of either nonclear phenotype or ccRCC with sarcomatoid features. Outcome was assessed centrally by a dedicated research radiologist for determination of tumor response, progression-free survival (PFS), and overall survival (OS). RESULTS: Eighty-five patients received temsirolimus (n = 59) or everolimus (n = 26). Nonclear-cell phenotypes included papillary (n = 14), chromophobe (n = 9), collecting duct (n = 4), translocation-associated (n = 3), and unclassified (n = 32) RCC. Twenty-three patients had clear-cell histology with sarcomatoid features. The response rate in assessable patients (n = 82) was 7% (all partial responses); 49% of patients achieved stable disease, and 44% had progressive disease as their best response. Tumor shrinkage was observed in 26 patients (32%). Median PFS and OS were 2.9 and 8.7 months, respectively. Nine patients (11%) were treated for ≥1 year, including cases of papillary (n = 3), chromophobe (n = 2), unclassified (n = 3) RCC, and ccRCC with sarcomatoid features (n = 1). No tumor shrinkages were observed for patients with collecting duct or translocation-associated RCC. CONCLUSIONS: A subset of patients with nonclear-cell and sarcomatoid variant ccRCC subtypes benefit from mTOR inhibitors, but most have poor outcome. Histologic subtype does not appear to be helpful in selecting patients for rapalog therapy. Future efforts should include the identification of predictive tissue biomarkers.
BACKGROUND: The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in patients with clear-cell histology (ccRCC). We assessed outcome with these mammalian target of rapamicin (mTOR) inhibitors in two subsets of kidney cancer: sarcomatoid variant ccRCC and nonclear-cell RCC. PATIENTS AND METHODS: Baseline clinical features, information on prior treatment, and histologic subtypes were collected for patients previously treated with rapalogs for metastatic RCC of either nonclear phenotype or ccRCC with sarcomatoid features. Outcome was assessed centrally by a dedicated research radiologist for determination of tumor response, progression-free survival (PFS), and overall survival (OS). RESULTS: Eighty-five patients received temsirolimus (n = 59) or everolimus (n = 26). Nonclear-cell phenotypes included papillary (n = 14), chromophobe (n = 9), collecting duct (n = 4), translocation-associated (n = 3), and unclassified (n = 32) RCC. Twenty-three patients had clear-cell histology with sarcomatoid features. The response rate in assessable patients (n = 82) was 7% (all partial responses); 49% of patients achieved stable disease, and 44% had progressive disease as their best response. Tumor shrinkage was observed in 26 patients (32%). Median PFS and OS were 2.9 and 8.7 months, respectively. Nine patients (11%) were treated for ≥1 year, including cases of papillary (n = 3), chromophobe (n = 2), unclassified (n = 3) RCC, and ccRCC with sarcomatoid features (n = 1). No tumor shrinkages were observed for patients with collecting duct or translocation-associated RCC. CONCLUSIONS: A subset of patients with nonclear-cell and sarcomatoid variant ccRCC subtypes benefit from mTOR inhibitors, but most have poor outcome. Histologic subtype does not appear to be helpful in selecting patients for rapalog therapy. Future efforts should include the identification of predictive tissue biomarkers.
Authors: Ana M Molina; Satish K Tickoo; Nicole Ishill; Michael J Trinos; Lawrence H Schwartz; Sujata Patil; Darren R Feldman; Victor E Reuter; Paul Russo; Robert J Motzer Journal: Am J Clin Oncol Date: 2011-10 Impact factor: 2.339
Authors: Badar M Mian; Nishin Bhadkamkar; Joel W Slaton; Peter W T Pisters; Danai Daliani; David A Swanson; Louis L Pisters Journal: J Urol Date: 2002-01 Impact factor: 7.450
Authors: M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin Journal: Am J Surg Pathol Date: 2001-03 Impact factor: 6.394
Authors: Brian Shuch; Gennady Bratslavsky; Joanna Shih; Srinivas Vourganti; David Finley; Brandon Castor; Eric Treat; W Marston Linehan; Allan J Pantuck; Jonathan W Said; Arie S Belldegrun Journal: BJU Int Date: 2012-01-05 Impact factor: 5.588
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ali Reza Golshayan; Saby George; Daniel Y Heng; Paul Elson; Laura S Wood; Tarek M Mekhail; Jorge A Garcia; Hakan Aydin; Ming Zhou; Ronald M Bukowski; Brian I Rini Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226
Authors: Martin H Voss; Ana M Molina; Ying-Bei Chen; Kaitlin M Woo; Joshua L Chaim; Devyn T Coskey; Almedina Redzematovic; Patricia Wang; William Lee; S Duygu Selcuklu; Chung-Han Lee; Michael F Berger; Satish K Tickoo; Victor E Reuter; Sujata Patil; James J Hsieh; Robert J Motzer; Darren R Feldman Journal: J Clin Oncol Date: 2016-11-10 Impact factor: 44.544
Authors: Jianing Xu; Can G Pham; Steven K Albanese; Yiyu Dong; Toshinao Oyama; Chung-Han Lee; Vanessa Rodrik-Outmezguine; Zhan Yao; Song Han; David Chen; Daniel L Parton; John D Chodera; Neal Rosen; Emily H Cheng; James J Hsieh Journal: J Clin Invest Date: 2016-08-02 Impact factor: 14.808
Authors: Yasser Ged; Ying-Bei Chen; Andrea Knezevic; Jozefina Casuscelli; Almedina Redzematovic; Renzo G DiNatale; Maria I Carlo; Chung-Han Lee; Darren R Feldman; Sujata Patil; A Ari Hakimi; Paul Russo; Robert J Motzer; Martin H Voss Journal: Clin Genitourin Cancer Date: 2019-04-01 Impact factor: 2.872
Authors: Sumanta K Pal; Miaoling He; Tommy Tong; Huiqing Wu; Xueli Liu; Clayton Lau; Jin-Hui Wang; Charles Warden; Xiwei Wu; Sabina Signoretti; Toni K Choueiri; Jose A Karam; Jeremy O Jones Journal: Mol Cancer Res Date: 2014-09-02 Impact factor: 5.852
Authors: Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri Journal: Eur Urol Date: 2015-11-26 Impact factor: 20.096
Authors: Samantha Jane Wala; Jason Raj Karamchandani; Rola Saleeb; Andrew Evans; Qiang Ding; Rania Ibrahim; Michael Jewett; Maria Pasic; Antonio Finelli; Kenneth Pace; Evi Lianidou; George Makram Yousef Journal: Mol Oncol Date: 2015-05-14 Impact factor: 6.603
Authors: Javier Puente; Xavier García Del Muro; Álvaro Pinto; Nuria Láinez; Emilio Esteban; José Ángel Arranz; Enrique Gallardo; María José Méndez; Pablo Maroto; Enrique Grande; Cristina Suárez Journal: Target Oncol Date: 2016-04 Impact factor: 4.493